Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Microbiology & Infectious Diseases
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Mullein Leaf Extract Shows Antibacterial Promise
February 2026
Mullein leaf extract showed the strongest antibacterial activity against resistant E. coli and Enterococcus in lab tests.
Read more
3 Sep 2025
Rare Bacterium Identified in Recurrent Breast Abscess
A rare gram-positive bacterium, Lawsonella clevelandensis, has been identified as the cause of a recurrent breast abscess in a middle-aged woman, underscoring the importance of molecular diagnostics for accurate identification of difficult-to-culture pathogens.
1 Sep 2025
IDSA Guideline Update on Infliximab for Severe COVID-19
The latest clinical practice guideline update provides new recommendations on the use of infliximab for hospitalized adults with severe or critical COVID-19.
30 Aug 2025
Interferon Nasal Spray Shows Protective Effect Against COVID-19
Daily prophylaxis with interferon-alpha (IFN-α) nasal spray significantly reduced the risk of COVID-19 infection in adult patients with cancer, according to findings from a randomized, double-blinded, placebo-controlled trial.
27 Aug 2025
Pre-Illness COVID Symptoms Predict Long COVID Risk
New evidence suggests that individuals with poorer pre-infection mental health and a higher burden of prior symptoms face a greater risk of developing long COVID, according to findings from a large national cohort study.
25 Aug 2025
Statistical Models Reveal Rising MRSA Infections
Methicillin-resistant Staphylococcus aureus (MRSA) infections are on the rise, with new statistical modeling showing significant links between community-acquired and hospital-acquired cases, age, and the COVID-19 pandemic.
23 Aug 2025
Bacterial Vaginosis Secretions Found to Enhance HIV Infection
Cervicovaginal secretions from young females with bacterial vaginosis (BV) were shown to enhance HIV infection in new research that underscores the biological mechanisms linking BV to increased HIV risk.
20 Aug 2025
Climate Changes Alter Flu Patterns After Pandemic
Pandemic-era disruptions have permanently altered the climate-influenza relationship, with new subtype-specific thresholds emerging in Southern China, according to a large-scale analysis spanning 2011 to 2024.
18 Aug 2025
When Surgery Becomes Essential in Severe
C. difficile
Severe Clostridioides difficile infection (CDI) can progress rapidly to organ failure and sepsis, and while most patients respond to antibiotic therapy, a minority face life-threatening disease that may require surgical intervention.
Loading posts...
« Previous
1
…
9
10
11
12
13
…
31
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View